MA38295B1 - Dérivé d'azole et de benzène - Google Patents
Dérivé d'azole et de benzèneInfo
- Publication number
- MA38295B1 MA38295B1 MA38295A MA38295A MA38295B1 MA 38295 B1 MA38295 B1 MA 38295B1 MA 38295 A MA38295 A MA 38295A MA 38295 A MA38295 A MA 38295A MA 38295 B1 MA38295 B1 MA 38295B1
- Authority
- MA
- Morocco
- Prior art keywords
- diseases
- compound
- xanthine oxidase
- relates
- diseases including
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
L'invention concerne un composé de formule (i) ou son sel pharmaceutiquement acceptable, qui présente une excellente activité inhibitrice sur la xanthine oxydase et est utilisé comme agent thérapeutique ou agent prophylactique pour les maladies associées à la xanthine oxydase, par exemple la goutte, l'hyperuricémie, le syndrome de lyse tumorale, la lithiase urinaire, l'hypertension, la dyslipidémie, le diabète, les maladies cardiovasculaires dont l'artériosclérose et l'insuffisance cardiaque, les maladies rénales dont la néphropathie diabétique, les maladies respiratoires dont la bronchopneumopathie chronique obstructive, les maladies inflammatoires chroniques de l'intestin ou les maladies auto-immunes. L'invention concerne également un médicament ou une composition pharmaceutique comprenant le composé ou le sel pour principe actif.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013017167 | 2013-01-31 | ||
| PCT/JP2014/052154 WO2014119681A1 (fr) | 2013-01-31 | 2014-01-30 | Dérivé d'azole et de benzène |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38295A1 MA38295A1 (fr) | 2017-12-29 |
| MA38295B1 true MA38295B1 (fr) | 2018-04-30 |
Family
ID=51262388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38295A MA38295B1 (fr) | 2013-01-31 | 2014-01-30 | Dérivé d'azole et de benzène |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9388174B2 (fr) |
| EP (1) | EP2952513B1 (fr) |
| JP (1) | JP5734532B2 (fr) |
| KR (1) | KR102199258B1 (fr) |
| CN (1) | CN104968662B (fr) |
| AR (1) | AR095098A1 (fr) |
| AU (1) | AU2014213396B2 (fr) |
| BR (1) | BR112015018033B1 (fr) |
| CA (1) | CA2897928C (fr) |
| CL (1) | CL2015002117A1 (fr) |
| CY (1) | CY1122015T1 (fr) |
| DK (1) | DK2952513T3 (fr) |
| ES (1) | ES2744817T3 (fr) |
| HK (1) | HK1215806A1 (fr) |
| HR (1) | HRP20191554T1 (fr) |
| HU (1) | HUE047028T2 (fr) |
| IL (2) | IL239940B (fr) |
| LT (1) | LT2952513T (fr) |
| MA (1) | MA38295B1 (fr) |
| ME (1) | ME03516B (fr) |
| MX (1) | MX364483B (fr) |
| MY (1) | MY181731A (fr) |
| NZ (1) | NZ709407A (fr) |
| PE (1) | PE20151329A1 (fr) |
| PH (2) | PH12015501640B1 (fr) |
| PL (1) | PL2952513T3 (fr) |
| PT (1) | PT2952513T (fr) |
| RS (1) | RS59371B1 (fr) |
| RU (1) | RU2641891C2 (fr) |
| SA (1) | SA515360829B1 (fr) |
| SG (1) | SG11201505993PA (fr) |
| SI (1) | SI2952513T1 (fr) |
| TW (1) | TWI606048B (fr) |
| UA (1) | UA117124C2 (fr) |
| WO (1) | WO2014119681A1 (fr) |
| ZA (1) | ZA201505240B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3239134T (pt) | 2013-01-31 | 2021-01-28 | Vertex Pharma | Piridona amidas como moduladores dos canais de sódio |
| EP3080134B1 (fr) | 2013-12-13 | 2018-08-01 | Vertex Pharmaceuticals Incorporated | Promédicaments d'amides de pyridone utiles en tant que modulateurs des canaux sodiques |
| CA2955577A1 (fr) * | 2014-07-30 | 2016-02-04 | Teijin Pharma Limited | Inhibiteur de xanthine-oxydase |
| PT3176166T (pt) | 2014-07-30 | 2019-02-04 | Teijin Pharma Ltd | Derivado azole-benzeno e seu cristal |
| NZ729045A (en) * | 2014-07-30 | 2022-05-27 | Teijin Pharma Ltd | Crystal of azole benzene derivative |
| ES2842577T3 (es) | 2016-02-19 | 2021-07-14 | Nezu Life Science Co Ltd | Fármaco terapéutico o profiláctico para la demencia |
| TW201828939A (zh) * | 2016-11-28 | 2018-08-16 | 日商帝人製藥股份有限公司 | 糖尿病性腎病之治療藥或預防藥 |
| KR102714561B1 (ko) | 2017-05-16 | 2024-10-10 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭 |
| JP2021512935A (ja) | 2018-02-12 | 2021-05-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 疼痛を処置する方法 |
| WO2021113627A1 (fr) | 2019-12-06 | 2021-06-10 | Vertex Pharmaceuticals Incorporated | Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques |
| JP2024522292A (ja) | 2021-06-04 | 2024-06-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2073981C (fr) | 1990-11-30 | 2002-01-08 | Shiro Kondo | Derives de 2-arylthiazole et composition pharmaceutique a base de ces derives |
| EP0779074B1 (fr) | 1995-04-07 | 2004-07-07 | Teijin Limited | Agent protecteur pour organe ou tissu |
| HUP9801692A3 (en) * | 1995-04-21 | 2001-11-28 | Neurosearch As | Benzimidazole compounds, pharmaceutical compositions containing them and their use for producing pharmaceutical compositions |
| JP2002105067A (ja) | 2000-09-28 | 2002-04-10 | Teijin Ltd | ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物 |
| EP1932833B1 (fr) | 2005-10-07 | 2012-08-01 | Kissei Pharmaceutical Co., Ltd. | Compose heterocyclique azote et composition pharmaceutique le contenant |
| WO2008126770A1 (fr) * | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | Procédé de production d'un dérivé d'acide triarylcarboxylique |
| AU2008239018B2 (en) | 2007-04-11 | 2013-09-05 | Kissei Pharmaceutical Co., Ltd. | 5-membered heterocyclic derivative and use thereof for medical purposes |
| WO2010018458A2 (fr) | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Dérivés de phénol et leurs procédés d'utilisation |
| WO2010128163A2 (fr) * | 2009-05-08 | 2010-11-11 | Pike Pharma Gmbh | Inhibiteurs à petite molécule du virus de la grippe a et b et de la réplication du virus respiratoire syncytial |
| WO2011101867A2 (fr) | 2010-02-19 | 2011-08-25 | Cadila Healthcare Limited | Sels essentiellement purs de fébuxostat et leurs procédés de préparation |
| US8969582B2 (en) | 2010-04-29 | 2015-03-03 | Dr. Reddy's Laboratories Ltd. | Preparation of febuxostat |
-
2014
- 2014-01-29 TW TW103103559A patent/TWI606048B/zh active
- 2014-01-30 PT PT14746209T patent/PT2952513T/pt unknown
- 2014-01-30 DK DK14746209.7T patent/DK2952513T3/da active
- 2014-01-30 CN CN201480006601.1A patent/CN104968662B/zh active Active
- 2014-01-30 AU AU2014213396A patent/AU2014213396B2/en active Active
- 2014-01-30 AR ARP140100314A patent/AR095098A1/es unknown
- 2014-01-30 PE PE2015001576A patent/PE20151329A1/es active IP Right Grant
- 2014-01-30 MX MX2015009655A patent/MX364483B/es active IP Right Grant
- 2014-01-30 LT LT14746209T patent/LT2952513T/lt unknown
- 2014-01-30 SI SI201431281T patent/SI2952513T1/sl unknown
- 2014-01-30 KR KR1020157019782A patent/KR102199258B1/ko active IP Right Grant
- 2014-01-30 US US14/442,752 patent/US9388174B2/en active Active
- 2014-01-30 RU RU2015132105A patent/RU2641891C2/ru active
- 2014-01-30 SG SG11201505993PA patent/SG11201505993PA/en unknown
- 2014-01-30 ES ES14746209T patent/ES2744817T3/es active Active
- 2014-01-30 MA MA38295A patent/MA38295B1/fr unknown
- 2014-01-30 ME MEP-2019-262A patent/ME03516B/fr unknown
- 2014-01-30 HU HUE14746209A patent/HUE047028T2/hu unknown
- 2014-01-30 BR BR112015018033-7A patent/BR112015018033B1/pt active IP Right Grant
- 2014-01-30 PL PL14746209T patent/PL2952513T3/pl unknown
- 2014-01-30 WO PCT/JP2014/052154 patent/WO2014119681A1/fr active Application Filing
- 2014-01-30 MY MYPI2015702266A patent/MY181731A/en unknown
- 2014-01-30 RS RSP20191244 patent/RS59371B1/sr unknown
- 2014-01-30 UA UAA201507650A patent/UA117124C2/uk unknown
- 2014-01-30 EP EP14746209.7A patent/EP2952513B1/fr active Active
- 2014-01-30 CA CA2897928A patent/CA2897928C/fr active Active
- 2014-01-30 JP JP2014557920A patent/JP5734532B2/ja active Active
- 2014-01-30 NZ NZ70940714A patent/NZ709407A/en not_active IP Right Cessation
-
2015
- 2015-07-14 IL IL239940A patent/IL239940B/en active IP Right Grant
- 2015-07-21 ZA ZA2015/05240A patent/ZA201505240B/en unknown
- 2015-07-23 PH PH12015501640A patent/PH12015501640B1/en unknown
- 2015-07-29 CL CL2015002117A patent/CL2015002117A1/es unknown
- 2015-07-29 SA SA515360829A patent/SA515360829B1/ar unknown
-
2016
- 2016-04-01 HK HK16103729.4A patent/HK1215806A1/zh unknown
-
2018
- 2018-02-05 PH PH12018500261A patent/PH12018500261A1/en unknown
- 2018-06-05 IL IL259824A patent/IL259824B/en active IP Right Grant
-
2019
- 2019-08-28 HR HRP20191554 patent/HRP20191554T1/hr unknown
- 2019-09-10 CY CY20191100944T patent/CY1122015T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38295B1 (fr) | Dérivé d'azole et de benzène | |
| RU2581367C2 (ru) | Соединения для лечения рака | |
| MA34897B1 (fr) | Formulations d'immunosupresseurs | |
| EA201491283A1 (ru) | Ингибитор регулирующей апоптотические сигналы киназы | |
| MA41434A (fr) | 7-benzyl-4-(4-(trifluorométhyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-one, ses sels et leur utilisation en thérapie | |
| MA38078A1 (fr) | Dérivé de pyridine | |
| EA201200876A1 (ru) | Новые антагонисты рецептора ccr2 и их применение | |
| WO2009054423A1 (fr) | Composé d'oxadiazolidinedione | |
| RU2609018C2 (ru) | Соединения для лечения рака | |
| MX2020000349A (es) | Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2). | |
| JP2015536997A5 (fr) | ||
| NO20085375L (no) | Nitrerte hetrosykliske forbindelser som endotelin-reseptorantagonist | |
| RU2017106058A (ru) | Кристаллическая форма азолбензольного производного | |
| MY176149A (en) | Pyrazole derivative | |
| AR101364A1 (es) | Derivado de ácido azolcarboxílico | |
| Gille et al. | Infusion of CSL112, a novel formulation of human apolipoprotein AI, in healthy subjects removes tissue cholesterol and directs its clearance | |
| Bernis et al. | The Effects of Bariatric Surgery on the Cardiovascular System | |
| MX2022002993A (es) | Rebamipida para usarse en la prevencion y/o tratamiento de la rigidez arterial. | |
| CA2855641A1 (fr) | Analogues de fluconazole optiquement actifs contenant des thiophenes comme agents antifongiques | |
| MA38479A1 (fr) | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante | |
| Scott et al. | HDM/SCT for AL Amyloidosis-A Single Institution 12 Year Experience | |
| TW202440551A (zh) | 一種THRβ受體激動劑化合物及其製備方法和用途 | |
| Loghman-Adham | Chronic Kidney Disease Epidemic and the Developing World | |
| TH126515A (th) | Ccr2 รีเซปเตอร์ แอนทากอนิสท์ชนิดใหม่ และการใช้ของมัน | |
| Evangelista et al. | Health risks and quality of life of female heart transplant recipients |